6 Recruiting Renal Cell Carcinoma Phase 1 / Phase 2 Clinical Trials
Active phase 1 / phase 2 studies for renal cell carcinoma enrolling across the USA. Verify eligibility and contact site coordinators.
All Renal Cell Carcinoma studiesPhase 1 / Phase 2 Studies for Renal Cell Carcinoma
🔵 Active, Not Recruiting Phase1 / Phase2
Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma
📍 Johns Hopkins — Baltimore, Maryland
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase1 / Phase2
Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.
📍 Duke Cancer Institute — Durham, North Carolina
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase1 / Phase2
Neo-adjuvant SABR for IVC Tumor Thrombus in Newly Diagnosed RCC
📍 University of Texas Southwestern Medical Center — Dallas, Texas
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase1 / Phase2
Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab
📍 UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase1 / Phase2
A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)
📍 Georgetown University Medical Center ( Site 1002) — Washington D.C., District of Columbia
View Study & Checklist ➔ 🟢 Recruiting Phase1 / Phase2
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
📍 UCSF Medical Center at Mission Bay ( Site 5008) — San Francisco, California
View Study & Checklist ➔